Infliximab Optimization for Crohn's Disease
Trial Summary
Do I need to stop my current medications to join the trial?
The trial protocol does not specify if you need to stop taking your current medications. However, if you are on oral corticosteroids, you may need to taper off by Week 14. It's best to discuss your specific medications with the trial team.
What data supports the effectiveness of the drug Infliximab for Crohn's disease?
Is infliximab safe for humans?
Infliximab, used for Crohn's disease and other conditions, has been studied in many trials and is generally considered safe, though it can cause side effects like headaches, fever, and chills. It may increase the risk of infections, but not serious ones, and has a low risk of causing drug-induced lupus, which resolves after stopping the drug.36789
How is the drug infliximab unique in treating Crohn's disease?
Infliximab is unique because it is a biologic drug that targets TNF (tumor necrosis factor), a protein involved in inflammation, making it effective for patients with moderate to severe Crohn's disease who do not respond to standard treatments. It can reduce the need for steroids and surgery, and is particularly useful for treating fistulas, which are abnormal connections between organs.1381011
What is the purpose of this trial?
This trial tests if using a computer program to decide infliximab doses is better and safer than standard dosing for patients with inflammatory bowel disease. The program helps doctors choose the best dose by looking at individual health details, aiming to keep the medication working well and prevent the disease from getting worse. Infliximab is commonly used to treat inflammatory bowel disease, and dose optimization has been shown to improve treatment outcomes.
Eligibility Criteria
The OPTIMIZE Trial is for males and females aged 16-80 with moderately to severely active Crohn's Disease. Participants must have certain disease markers like elevated CRP or fecal calprotectin, and no prior significant use of Infliximab. Exclusions include those with specific CD complications, infections like tuberculosis or hepatitis B/C, recent serious infections, cancer within the last 5 years (except some skin cancers), immunodeficiency disorders, high-dose steroid use without tapering plans, pregnancy or lactation.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either proactive infliximab optimization using a pharmacokinetic dashboard or standard of care infliximab dosing
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Infliximab
Infliximab is already approved in European Union, United States, Canada, Japan for the following indications:
- Ankylosing Spondylitis
- Crohn's Disease
- Ulcerative Colitis
- Psoriatic Arthritis
- Rheumatoid Arthritis
- Plaque Psoriasis
- Ankylosing Spondylitis
- Crohn's Disease
- Ulcerative Colitis
- Psoriatic Arthritis
- Rheumatoid Arthritis
- Plaque Psoriasis
- Ankylosing Spondylitis
- Crohn's Disease
- Ulcerative Colitis
- Psoriatic Arthritis
- Rheumatoid Arthritis
- Plaque Psoriasis
- Ankylosing Spondylitis
- Crohn's Disease
- Ulcerative Colitis
- Psoriatic Arthritis
- Rheumatoid Arthritis
- Plaque Psoriasis
Find a Clinic Near You
Who Is Running the Clinical Trial?
Beth Israel Deaconess Medical Center
Lead Sponsor
The Leona M. and Harry B. Helmsley Charitable Trust
Collaborator
Icahn School of Medicine at Mount Sinai
Collaborator